Figure 1
Figure 1. Distribution of cytogenetic abnormalities. Therapy-related AML (n = 179, A) and de novo AML (n = 2363, B; MDS-related cytogenetic abnormalities according to Swerdlow et al1).

Distribution of cytogenetic abnormalities. Therapy-related AML (n = 179, A) and de novo AML (n = 2363, B; MDS-related cytogenetic abnormalities according to Swerdlow et al1 ).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal